Dysregulation of KRAS signaling in pancreatic cancer is not associated with KRAS mutations and outcome

• Authors: LEMSTROVA Radmila; BRYNYCHOVA Veronika; HUGHES David J.; HLAVAS Viktor; DVORAK Pavel; DOHERTY Joanne E.; MURRAY Helena A.; CROCKARD Martin; OLIVERIUS martin; HLAVSA Jan; HONSOVA Eva; MAZANEC Jan; KALA Zdeněk; LOVECEK Martin; HAVLIK Roman; EHRMANN Jiri; STROUHAL Ondrej; SOUCEK Pavel; MELICHAR Bohuslav; MOHELNIKOVA-DUCHONOVA Beatrice
• Year of publication: 2017
• Type: Article in Periodical
• Magazine / Source: Oncology Letters
• MU Faculty or unit: Faculty of Medicine
• Doi: http://dx.doi.org/10.3892/ol.2017.6946
• Field: Surgery incl. transplantology
• Keywords: pancreatic ductal adenocarcinoma; KRAS; gene expression; mutation; overall survival
• Description: Pancreatic ductal adenocarcinoma (PDAC) is a tumor with a poor prognosis, and no targeted therapy is currently available. The aim of the present study was to investigate the prognostic significance of the expression of V-Ki-ras2 kirsten rat sarcoma viral oncogene homolog (KRAS), downstream signaling pathway genes and the association with clinical characteristics in PDAC patients undergoing radical surgery. Tumors and adjacent non-neoplastic pancreatic tissues were examined in 45 patients with histologically verified PDAC. KRAS and B-Raf proto-oncogene, serine/threonine kinase (BRAF) gene mutation analysis was performed using the KRAS/BRAF/phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha array.